1.39
Cerus Corp stock is traded at $1.39, with a volume of 528.07K.
It is up +2.21% in the last 24 hours and up +5.30% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
See More
Previous Close:
$1.36
Open:
$1.37
24h Volume:
528.07K
Relative Volume:
0.46
Market Cap:
$265.71M
Revenue:
$156.37M
Net Income/Loss:
$-37.49M
P/E Ratio:
-6.619
EPS:
-0.21
Net Cash Flow:
$-47.77M
1W Performance:
+2.21%
1M Performance:
+5.30%
6M Performance:
-29.44%
1Y Performance:
-41.60%
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CERS
Cerus Corp
|
1.39 | 259.98M | 156.37M | -37.49M | -47.77M | -0.21 |
![]()
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
![]()
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.69B | 4.15B | 623.10M | 6.95 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-24 | Initiated | Craig Hallum | Buy |
Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Oct-08-20 | Resumed | BTIG Research | Buy |
Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
Feb-26-20 | Initiated | BTIG Research | Buy |
Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
Aug-28-19 | Initiated | Stifel | Buy |
Aug-23-19 | Resumed | Stephens | Overweight |
Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
Dec-08-17 | Resumed | BTIG Research | Neutral |
Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
May-02-14 | Reiterated | MLV & Co | Buy |
Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-15-13 | Reiterated | MLV & Co | Buy |
Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
Nov-10-11 | Reiterated | MLV & Co | Buy |
Jun-03-11 | Initiated | Wedbush | Outperform |
Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
What makes Cerus Corporation stock price move sharplyFree Stock Market Courses - Newser
Cerus Corporation Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia
What drives Cerus Corporation stock priceFree Stock Market Mentorship - Autocar Professional
Why Cerus Corporation stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser
How Cerus Corporation stock performs during market volatilityDouble Profit With Half Risk - Newser
What analysts say about Cerus Corporation stockConsistent triple returns - Autocar Professional
Is Cerus Corporation a good long term investmentSuperior trading gains - jammulinksnews.com
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025 - Yahoo Finance
Cerus stock rises after securing additional $7.2 million DoD contract By Investing.com - Investing.com Canada
Cerus stock rises after securing additional $7.2 million DoD contract - Investing.com
Cerus receives $7.2 million DoD contract amendment for trauma treatment - Investing.com
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury - Yahoo Finance
Cerus Q4 2024 slides: Positive EBITDA achieved amid 15% revenue growth - Investing.com Canada
Cerus Q4 2024 slides: Positive EBITDA achieved amid 15% revenue growth By Investing.com - Investing.com South Africa
Cerus Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance
Cerus advances European regulatory review for INTERCEPT RBC system - Investing.com
Cerus Provides INTERCEPT Red Blood Cell CE Mark Application Update - Investing.com
Cerus Appoints New Chair Following Board Retirement - TipRanks
Daily Market Movement: Cerus Corp (CERS) Sees a 6.82 Increase, Closing at 1.41 - DWinneX
26,884 Shares in Cerus Co. (NASDAQ:CERS) Purchased by Pallas Capital Advisors LLC - Defense World
Cerus Corporation Celebrates World Blood Donor Day 2025 - Yahoo Finance
Cerus at Goldman Sachs Conference: Pathogen Reduction Leadership - Investing.com
Cerus at Goldman Sachs Conference: Pathogen Reduction Leadership By Investing.com - Investing.com Canada
Cerus Corp shareholders approve equity plan amendment By Investing.com - Investing.com South Africa
Cerus Corp shareholders approve equity plan amendment - Investing.com
Sigyn Therapeutics (OTCMKTS:SIGY) & Cerus (NASDAQ:CERS) Head to Head Comparison - Defense World
Two Sigma Investments LP Acquires 326,605 Shares of Cerus Co. (NASDAQ:CERS) - Defense World
Mackenzie Financial Corp Acquires 17,704 Shares of Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) - Defense World
3 Promising Penny Stocks With Market Caps Over $90M - Yahoo Finance
Cerus Management Takes Stage at Goldman Sachs Healthcare Conference: Key Updates Coming June 11 - Stock Titan
Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Yahoo Finance
Cantor Fitzgerald maintains Cerus stock rating due to regulatory approvals By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Cerus stock rating due to regulatory approvals - Investing.com
Cerus to present new INTERCEPT Blood System data at ISBT Congress - Investing.com
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan - Yahoo Finance
Cerus (CERS) Gains French and Swiss Regulatory Approvals for New Device | CERS Stock News - GuruFocus
Cerus gains regulatory nods for blood safety device in Europe - Investing.com
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device - Business Wire
Cerus wins regulatory approvals for next-gen blood safety device in France, Switzerland - Medical Economics
Cerus Co. (NASDAQ:CERS) Stake Boosted by Jane Street Group LLC - Defense World
When Should You Buy Cerus Corporation (NASDAQ:CERS)? - Yahoo Finance
Price T Rowe Associates Inc. MD Buys 34,694 Shares of Cerus Co. (NASDAQ:CERS) - Defense World
Stifel Financial Corp Grows Stock Position in Cerus Co. (NASDAQ:CERS) - Defense World
Raymond James Financial Inc. Acquires Shares of 244,073 Cerus Co. (NASDAQ:CERS) - Defense World
Closing Strong: Cerus Corp (CERS) Ends at 1.25, Down -3.85 from Last Close - DWinneX
Cerus Corporation Announces First Quarter 2025 Financial Results - ADVFN
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
JPMorgan Chase & Co. Grows Stock Holdings in Cerus Co. (NASDAQ:CERS) - Defense World
Cerus Corporation (NASDAQ:CERS) Just Reported, And Analysts Assigned A US$4.25 Price Target - Yahoo Finance
Cerus Corporation (NASDAQ:CERS) Q1 2025 Earnings Call Transcript - Insider Monkey
Cerus Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cerus Corp Stock (CERS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Jensen Chrystal | Chief Legal Officer |
Mar 13 '25 |
Sale |
1.45 |
18,949 |
27,476 |
813,369 |
Jayaraman Vivek K | Chief Operating Officer |
Mar 14 '25 |
Sale |
1.45 |
46,004 |
66,706 |
1,431,326 |
Jayaraman Vivek K | Chief Operating Officer |
Mar 13 '25 |
Sale |
1.45 |
29,985 |
43,478 |
1,477,330 |
Greenman William Mariner | President and CEO |
Mar 14 '25 |
Sale |
1.45 |
122,827 |
178,099 |
4,115,845 |
Greenman William Mariner | President and CEO |
Mar 13 '25 |
Sale |
1.45 |
71,086 |
103,075 |
4,238,672 |
Green Kevin Dennis | Chief Financial Officer |
Mar 14 '25 |
Sale |
1.45 |
36,740 |
53,273 |
875,867 |
Green Kevin Dennis | Chief Financial Officer |
Mar 13 '25 |
Sale |
1.45 |
23,147 |
33,563 |
912,607 |
Benjamin Richard J | Chief Medical Officer |
Mar 14 '25 |
Sale |
1.45 |
30,075 |
43,609 |
685,775 |
Benjamin Richard J | Chief Medical Officer |
Mar 13 '25 |
Sale |
1.45 |
18,949 |
27,476 |
715,850 |
Jensen Chrystal | Chief Legal Officer |
Mar 07 '25 |
Sale |
1.50 |
27,457 |
41,131 |
832,318 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):